Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06178614 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-87890387 for Advanced Solid Tumors
A Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 6
- Study locations
NCT06178614: Recruiting Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by Janssen Research & Development.
NCT06178614 is a Phase 1 study of Neoplasms and Advanced Solid Tumors that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 200 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06178614, a Phase 1 study of Neoplasms and Advanced Solid Tumors, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
Primary Outcome
Number of participants with DLTs will be reported. The DLTs are adverse events including certain high grade non-hematologic or hematologic toxicities, or toxicities meeting other specific criteria.
Conditions Studied
Interventions
- DRUG JNJ-87890387
Study Locations (6)
Other
- Centre Leon Berard - Lyon
- Institut Gustave Roussy - Villejuif
- Hosp Univ Vall D Hebron - Barcelona
- Hosp. Univ. 12 de Octubre - Madrid
Michigan
- Start Midwest - Grand Rapids
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2029-02-07 |
| Phase | Phase 1 |
What NCT06178614 shows while recruiting
NCT06178614 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JNJ-87890387 is the first listed.
NCT06178614 lists 6 locations in 3 states (Other, Michigan, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06178614 about?
NCT06178614 is a clinical study titled "A Study of JNJ-87890387 for Advanced Solid Tumors". The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
What is the current status of trial NCT06178614?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2023-12-14. Estimated completion is 2029-02-07.
What conditions does trial NCT06178614 study?
This clinical trial studies the following conditions: Neoplasms, Advanced Solid Tumors.
What interventions are being tested in trial NCT06178614?
The interventions under investigation include: JNJ-87890387 (DRUG).
Who is sponsoring clinical trial NCT06178614?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06178614 being conducted?
This trial has 6 study locations across Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06178614's enrollment target sits among peer trials
200 49th of 158 higher than 109 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI